Publications by authors named "Sumner Abraham"

2 Publications

  • Page 1 of 1

Re-thinking morbidity and mortality.

Diagnosis (Berl) 2020 Jul 6. Epub 2020 Jul 6.

Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.

Despite the breadth of patient safety initiatives, physicians talking about their mistakes to other physicians is a difficult thing to do. This difficulty may be exacerbated by a limited exposure to how to analyze and discuss mistakes and respond in a productive way. At the University of Virginia, we recognized the importance of understanding cognitive biases for residents in both their clinical and personal professional development. We re-designed our resident led morbidity and mortality (M&M) conference using a model that integrates dual-process theory and metacognition to promote informed reflection and analysis of cognitive diagnostic errors. We believe that structuring M&M in this way builds a culture that encourages reflection together to learn our most difficult diagnostic errors and to engage in where our thought processes went wrong. In slowly building this culture, we hope to inoculate residents with the habits of mind that can best protect them from harmful biases in their clinical reasoning while instilling a culture of self-reflection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1515/dx-2020-0040DOI Listing
July 2020

Safety and effectiveness of apixaban compared to warfarin in dialysis patients.

Res Pract Thromb Haemost 2018 Apr 26;2(2):291-298. Epub 2018 Mar 26.

Division of Hematology & Oncology University of Virginia Charlottesville VA USA.

The use of apixaban for stroke prophylaxis or for the treatment of venous thromboembolism in end stage renal disease (ESRD) patients maintained on dialysis is based on one single-dose pharmacokinetic study. There is a deficiency of clinical evidence supporting safety in this population. The purpose of this study was to determine the safety and efficacy of apixaban compared with warfarin in dialysis patients. This is a retrospective cohort study conducted at the University of Virginia Medical Center. A total of 124 ESRD patients maintained on dialysis who either received apixaban (n = 74) or warfarin (n = 50) between January 1, 2014 and October 31, 2016 were included in the study. We used multivariable logistic regression to compare the likelihood of patients experiencing a bleeding event based on anticoagulant therapy. The apixaban group experienced fewer overall bleeding events than the warfarin group (18.9% vs 42.0%; =.01); this significant difference persisted in adjusted analysis (OR = 0.15; 95% CI = 0.05-0.46; =.001). Major bleeding events were less frequent in the apixaban group compared with patients on warfarin (5.4% vs 22.0%; =.01). There were no recurrent ischemic strokes in either groups. A lower, non-significant, incidence of recurrent VTE was found in patients on apixaban compared with warfarin (4.4% vs 28.6%; =.99). Compared to warfarin, our findings suggest that apixaban is a safe and effective alternative in patients with ESRD maintained on dialysis, with apixaban patients experiencing fewer bleeding events than warfarin patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/rth2.12083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055495PMC
April 2018